Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial

CONCLUSION: In participants with past or active neoplasms, BNT162b2 vaccine has a similar efficacy and safety profile as in the overall trial population. These results can inform BNT162b2 use during the COVID-19 pandemic and future trials in participants with cancer. Clinical trial number: NCT04368728.PMID:35131133 | PMC:PMC8702495 | DOI:10.1016/j.vaccine.2021.12.046

Source: Vaccine - February 8, 2022 Category: Allergy & Immunology Authors: Stephen J Thomas John L Perez Stephen P Lockhart Subramanian Hariharan Nicholas Kitchin Ruth Bailey Katherine Liau Eleni Lagkadinou Özlem Türeci Ugur Şahin Xia Xu Kenneth Koury Samuel S Dychter Claire Lu Teresa C Gentile William C Gruber Source Type: research